(Alliance News) - Liquid biopsy company Angle PLC on Tuesday reported that research in Australia found its Parsortix blood sampling system to be useful in assessing patients with a type of skin cancer.
Research by the Edith Cowan University in Perth found that out of 28 melanoma patients, those who had a positive score on a Parsortix circulating tumour cells test were more likely to die within a 60-week follow-up than those who had a negative score.
CTCs are cells which form a cancer tumour area and move to other parts of the body.
Angle said: "The researchers believe this opens the potential for liquid biopsy to be used for prognostication (assessing prognosis) and treatment response monitoring in melanoma."
Angle added the study found that Parsortix compares favourably to other blood sampling systems on the market.
"The research also compared results from the Parsortix system with some competing systems using matched samples and determined that Parsortix yielded the highest recovery of CTCs and had lower white blood cell background," the company explained.
Chief Executive Andrew Newland added: "This is another great example of one of our customers developing new pilot studies to show the potential clinical utility of Parsortix in other cancer types and applications. Melanoma is an important opportunity for future use of Parsortix."
Earlier in January, Angle said it expects the cancer treatment to secure US Food & Drug Administration consent later this year, following a "successful" face-to-face meeting with the regulator.
Shares in Angle were 4.5% higher at 72.12 pence each in London on Tuesday morning.
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Angle (AGL)